EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer.


We retrospectively analyzed the expression of epidermal growth factor receptor (EGFR) as a prognostic marker to predict neoadjuvant chemotherapy response and survival among breast cancer subtypes. We used immunohistochemical profiles to subtype the patients. EGFR expression was determined using immunohistochemistry. All patients received an anthracycline… (More)


6 Figures and Tables